Bevacizumab for Metastatic Colorectal Cancer: A NICE Single Technology Appraisal

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of bevacizumab (Roche Products) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of patients with metastatic colorectal cancer (mCRC), as part of the Institute’s Single...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics 2012-12, Vol.30 (12), p.1119-1132
Hauptverfasser:	Whyte, Sophie, Pandor, Abdullah, Stevenson, Matt
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - economics Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - economics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Chemotherapy Colorectal Neoplasms - drug therapy Colorectal Neoplasms - economics Colorectal Neoplasms - pathology Cost-Benefit Analysis Decision Making Decision Support Techniques Gastroenterology. Liver. Pancreas. Abdomen Health Administration Health Economics Health technology assessment Humans Medical sciences Medicine & Public Health Models, Economic Neoplasm Metastasis Pharmacoeconomics and Health Outcomes Pharmacology. Drug treatments Public Health Quality of Life Research Randomized Controlled Trials as Topic Review Article Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Survival Rate Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!